INS and type 2 diabetes mellitus: Figure 2 shows the impact of the insulin pocket dosing guide on the utilization of basal/bolus insulin for management of type-2 diabetes.  During the pilot phase of the study, there was a steady increase in basal/bolus insulin for the management of type-2 diabetes, peaking at 58.1% of insulin orders in February 2011. During the pilot phase, the overall use of basal/bolus insulin increased from 6.0% during the previous year to 35.7% (P < 0.01).